Drug intelligence / Profile preview

mometasone furoate nasal spray

Development stage: Approved
Lead developer: Merck
Modality: Small Molecules
Administration: Intranasal

Overview

Mometasone furoate nasal spray is a corticosteroid medication used to prevent and relieve symptoms of seasonal allergies (allergic rhinitis) such as sneezing, runny, stuffy, or itchy nose. It's also used to treat nasal polyps and chronic rhinosinusitis with nasal polyps in adults. The medication works by blocking the release of certain natural substances that cause allergy symptoms and by reducing inflammation in the nasal passages.

Brand names: NasonexNasonex 24hr AllergyNasonex24hr AllergyNasonex-24hr AllergyPropelSinuvaPropel MiniPropel Contour
Other names: mometasone nasalmometasone furoate nasalmometasone furoate monohydrate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on mometasone furoate nasal spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mometasone furoate nasal spray.

Explore the full profile